source
- Novo Nordisk’s anti-inflammatory drug ziltivekimab fails to cut heart events, but cardiologists still eye inflammation pathwayNovo Nordisk reported that its experimental monoclonal antibody ziltivekimab lowered interleukin‑6 levels in the ZEUS trial but did not reduce heart attacks, strokes or cardiovascular deaths compar…
- Democrats Take House, Raising Questions for Biopharma PolicyDemocrats secured control of Congress in a wave election held on Tuesday, shifting the political balance in Washington. The change is expected to influence the regulatory landscape for the biophar…